Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_assertion type Assertion NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_head.
- NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_assertion description "[Moreover, dominant negative cross talk between ectopic wild-type p53 and recently identified dominant p53 mutants and splice variants of p63 and p73--which are frequently overexpressed in ovarian cancers--could seriously compromise the effectiveness of p53 gene therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_provenance.
- NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_assertion evidence source_evidence_literature NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_provenance.
- NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_assertion SIO_000772 12850192 NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_provenance.
- NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_assertion wasDerivedFrom befree-20140225 NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_provenance.
- NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_assertion wasGeneratedBy ECO_0000203 NP899716.RAvr-cREc8TtdT7_wnPk4Oz7e5JH00TbaUWsu1O-xfIpo130_provenance.